{"pmid":32350226,"title":"An assessment of real-time RT-PCR kits for SARS-CoV-2 detection.","text":["An assessment of real-time RT-PCR kits for SARS-CoV-2 detection.","The COVID-19 outbreak caused by SARS-CoV-2 in Wuhan (China) in December 2019 is currently spreading rapidly and globally. We recently reported a laboratory diagnostic protocol for SARS-CoV-2 based on real-time RT-PCR assays using two primer sets, N and N2. On 30-31 January 2020, the protocol and reagents for these assays were distributed to local public health institutes and quarantine depots in Japan, and nationwide, SARS-CoV-2 diagnostic testing was started. For further validation, the assays were compared with the commercially available kits using SARS CoV-2 viral RNA and the clinical specimens obtained from COVID19-suspected individuals. The LightMix Modular SARS and Wuhan CoV E-gene (LN S&W-E) assay was highly sensitive for SARS-CoV-2, as was the N2 set, and both assays had perfectly consistent results with the clinical specimens. While the LM S&W-E set targets the highly conserved region of the E gene in SARS-CoV and SARS-CoV-2, the N2 set was designed to target the unique region in the SARS-CoV-2 N gene. Thus, the N2 set has high specificity and sensitivity for SARS-CoV-2 detection. These indicate that the protocol using the N and N2 sets is comparable to commercially available kits and is reliable for the laboratory diagnosis of COVID-19.","Jpn J Infect Dis","Okamaoto, Kiyoko","Shirato, Kazuya","Nao, NagaNaganori","Saito, Shinji","Kageyama, Tsutomu","Hasegawa, Hideki","Suzuki, Tadaki","Matsuyama, Shutoku","Takeda, Makoto","32350226"],"abstract":["The COVID-19 outbreak caused by SARS-CoV-2 in Wuhan (China) in December 2019 is currently spreading rapidly and globally. We recently reported a laboratory diagnostic protocol for SARS-CoV-2 based on real-time RT-PCR assays using two primer sets, N and N2. On 30-31 January 2020, the protocol and reagents for these assays were distributed to local public health institutes and quarantine depots in Japan, and nationwide, SARS-CoV-2 diagnostic testing was started. For further validation, the assays were compared with the commercially available kits using SARS CoV-2 viral RNA and the clinical specimens obtained from COVID19-suspected individuals. The LightMix Modular SARS and Wuhan CoV E-gene (LN S&W-E) assay was highly sensitive for SARS-CoV-2, as was the N2 set, and both assays had perfectly consistent results with the clinical specimens. While the LM S&W-E set targets the highly conserved region of the E gene in SARS-CoV and SARS-CoV-2, the N2 set was designed to target the unique region in the SARS-CoV-2 N gene. Thus, the N2 set has high specificity and sensitivity for SARS-CoV-2 detection. These indicate that the protocol using the N and N2 sets is comparable to commercially available kits and is reliable for the laboratory diagnosis of COVID-19."],"journal":"Jpn J Infect Dis","authors":["Okamaoto, Kiyoko","Shirato, Kazuya","Nao, NagaNaganori","Saito, Shinji","Kageyama, Tsutomu","Hasegawa, Hideki","Suzuki, Tadaki","Matsuyama, Shutoku","Takeda, Makoto"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350226","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.7883/yoken.JJID.2020.108","keywords":["covid-19","sars-cov-2","real-time rt-pcr"],"locations":["Wuhan","China","Japan"],"countries":["Japan","China"],"countries_codes":["JPN|Japan","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495593218048,"score":9.490897,"similar":[{"pmid":32269100,"title":"Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit.","text":["Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit.","Nearly 400,000 people worldwide are known to have been infected with SARS-CoV-2 beginning in December 2019. The virus has now spread to over 168 countries including the United States, where the first cluster of cases was observed in the Seattle metropolitan area in Washington. Given the rapid increase in the number of cases in many localities, the availability of accurate, high-throughput SARS-CoV-2 testing is vital to efforts to manage the current public health crisis. In the course of optimizing SARS-CoV-2 testing performed by the University of Washington Clinical Virology Lab (UW Virology Lab), we evaluated assays using seven different primer/probe sets and one assay kit. We found that the most sensitive assays were those that used the E-gene primer/probe set described by Corman et al. (Eurosurveillance 25 (3), 2020, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045) and the N2 set developed by the CDC (Division of Viral Diseases, Centers for Disease Control and Prevention, 2020, https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pd f). All assays tested were found to be highly specific for SARS-CoV-2, with no cross-reactivity with other respiratory viruses observed in our analyses regardless of the primer/probe set or kit used. These results will provide valuable information to other clinical laboratories who are actively developing SARS-CoV-2 testing protocols at a time when increased testing capacity is urgently needed worldwide.","J Clin Microbiol","Nalla, Arun K","Casto, Amanda M","Huang, Meei-Li W","Perchetti, Garrett A","Sampoleo, Reigran","Shrestha, Lasata","Wei, Yulun","Zhu, Haiying","Jerome, Keith R","Greninger, Alexander L","32269100"],"abstract":["Nearly 400,000 people worldwide are known to have been infected with SARS-CoV-2 beginning in December 2019. The virus has now spread to over 168 countries including the United States, where the first cluster of cases was observed in the Seattle metropolitan area in Washington. Given the rapid increase in the number of cases in many localities, the availability of accurate, high-throughput SARS-CoV-2 testing is vital to efforts to manage the current public health crisis. In the course of optimizing SARS-CoV-2 testing performed by the University of Washington Clinical Virology Lab (UW Virology Lab), we evaluated assays using seven different primer/probe sets and one assay kit. We found that the most sensitive assays were those that used the E-gene primer/probe set described by Corman et al. (Eurosurveillance 25 (3), 2020, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045) and the N2 set developed by the CDC (Division of Viral Diseases, Centers for Disease Control and Prevention, 2020, https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pd f). All assays tested were found to be highly specific for SARS-CoV-2, with no cross-reactivity with other respiratory viruses observed in our analyses regardless of the primer/probe set or kit used. These results will provide valuable information to other clinical laboratories who are actively developing SARS-CoV-2 testing protocols at a time when increased testing capacity is urgently needed worldwide."],"journal":"J Clin Microbiol","authors":["Nalla, Arun K","Casto, Amanda M","Huang, Meei-Li W","Perchetti, Garrett A","Sampoleo, Reigran","Shrestha, Lasata","Wei, Yulun","Zhu, Haiying","Jerome, Keith R","Greninger, Alexander L"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32269100","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1128/JCM.00557-20","locations":["United States","Seattle","Washington"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491841413120,"score":471.6177},{"pmid":32501535,"title":"Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole genome sequencing.","text":["Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole genome sequencing.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the COVID-19 pandemic. Accurate detection of SARS-CoV-2 using molecular assays is critical for patient management and the control of the COVID-19 pandemic. However, there is an increasing number of SARS-CoV-2 viruses with mutations at the primer or probe binding sites, and these mutations may affect the sensitivity of currently available real-time reverse transcription-polymerase chain reaction (RT-PCR) assays targeting the N, E, and ORF1a/b genes. Using sequence-independent single-primer amplification (SISPA) and nanopore whole-genome sequencing, we have found that the nsp1 gene, located at the 5' end of the SARS-CoV-2 genome, was highly expressed in the nasopharyngeal or saliva specimens of 9 COVID-19 patients of different clinical severity. Based on this finding, we have developed a novel nsp1 real-time RT-PCR assay. The primers and probes are highly specific for SARS-CoV-2. Validation with 101 clinical specimens showed that our nsp1 RT-PCR assay has a sensitivity of 93.1% (95% confidence interval, 86.2-97.2%), which was similar to those of N and E gene RT-PCR assays. The diagnostic specificity was 100% (95% CI, 92.9-100%). The addition of nsp1 for multi-target detection of SARS-CoV-2 can avoid false negative results due to mutations at the primers/probes binding sites of currently available RT-PCR assays. This article is protected by copyright. All rights reserved.","J Med Virol","Chan, Wan-Mui","Ip, Jonathan Daniel","Chu, Allen Wing-Ho","Yip, Cyril Chik-Yan","Lo, Lap-Sum","Chan, Kwok-Hung","Ng, Anthony Chin-Ki","Poon, Rosana Wing-Shan","To, Wing-Kin","Tsang, Owen Tak-Yin","Leung, Wai-Shing","Kwan, Mike Yat-Wah","Chua, Gilbert T","Chung, Tom Wai-Hin","Hung, Ivan Fan-Ngai","Kok, Kin-Hang","Cheng, Vincent Chi-Chung","Chan, Jasper Fuk-Woo","Yuen, Kwok-Yung","To, Kelvin Kai-Wang","32501535"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the COVID-19 pandemic. Accurate detection of SARS-CoV-2 using molecular assays is critical for patient management and the control of the COVID-19 pandemic. However, there is an increasing number of SARS-CoV-2 viruses with mutations at the primer or probe binding sites, and these mutations may affect the sensitivity of currently available real-time reverse transcription-polymerase chain reaction (RT-PCR) assays targeting the N, E, and ORF1a/b genes. Using sequence-independent single-primer amplification (SISPA) and nanopore whole-genome sequencing, we have found that the nsp1 gene, located at the 5' end of the SARS-CoV-2 genome, was highly expressed in the nasopharyngeal or saliva specimens of 9 COVID-19 patients of different clinical severity. Based on this finding, we have developed a novel nsp1 real-time RT-PCR assay. The primers and probes are highly specific for SARS-CoV-2. Validation with 101 clinical specimens showed that our nsp1 RT-PCR assay has a sensitivity of 93.1% (95% confidence interval, 86.2-97.2%), which was similar to those of N and E gene RT-PCR assays. The diagnostic specificity was 100% (95% CI, 92.9-100%). The addition of nsp1 for multi-target detection of SARS-CoV-2 can avoid false negative results due to mutations at the primers/probes binding sites of currently available RT-PCR assays. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chan, Wan-Mui","Ip, Jonathan Daniel","Chu, Allen Wing-Ho","Yip, Cyril Chik-Yan","Lo, Lap-Sum","Chan, Kwok-Hung","Ng, Anthony Chin-Ki","Poon, Rosana Wing-Shan","To, Wing-Kin","Tsang, Owen Tak-Yin","Leung, Wai-Shing","Kwan, Mike Yat-Wah","Chua, Gilbert T","Chung, Tom Wai-Hin","Hung, Ivan Fan-Ngai","Kok, Kin-Hang","Cheng, Vincent Chi-Chung","Chan, Jasper Fuk-Woo","Yuen, Kwok-Yung","To, Kelvin Kai-Wang"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501535","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26140","keywords":["covid-19","rt-pcr","sars-cov-2","diagnosis","nanopore sequencing","nsp1"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1668890966407249920,"score":420.08975},{"pmid":32482633,"title":"Clinical performance of the Luminex NxTAG CoV Extended Panel for SARS-CoV-2 detection in nasopharyngeal specimens of COVID-19 patients in Hong Kong.","text":["Clinical performance of the Luminex NxTAG CoV Extended Panel for SARS-CoV-2 detection in nasopharyngeal specimens of COVID-19 patients in Hong Kong.","In December 2019, the coronavirus disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in the Hubei Province of China and later spread all over the world. There was an urgent need of a high-throughput molecular testing for screening the COVID-19 patients in the community. The Luminex NxTAG CoV Extended Panel is a high-throughput FDA emergency use authorized molecular diagnostic assay for SARS-CoV-2 detection. This system targets three genes (ORF1ab, N and E gene) of SARS-CoV-2, ORF1ab region of SARS-CoV and ORF5 region of MERS-CoV.In this study, we evaluated the diagnostic performance of this system with nasopharyngeal swab specimens of 214 suspected COVID-19 patients in Hong Kong. The results were compared with our routine COVID-19 RT-PCR protocol with LightMix SarbecoV E-gene kit and an in-house RdRp/Hel RT-PCR assay. The NxTAG CoV Extended panel demonstrated a 97.8% sensitivity and 100% specificity to SARS-CoV-2 in nasopharyngeal specimens. On low viral load specimens, the sensitivity of the NxTAG panel could still maintain at 85.71%. High agreement was observed between the NxTAG panel and the routine COVID-19 RT-PCR protocol (kappa value = 0.98). Overall the E gene target of the NxTAG panel demonstrated the highest sensitivity among the three SARS-CoV-2 targets while the N gene targets demonstrated the least.In conclusion, the NxTAG CoV Extended Panel is simple to use and it has high diagnostic sensitivity and specificity to SARS-CoV-2 in nasopharyngeal specimens. we recommend this diagnostic system for high-throughput COVID-19 screening in the community.","J Clin Microbiol","Chen, Jonathan Hon-Kwan","Yip, Cyril Chik-Yan","Chan, Jasper Fuk-Woo","Poon, Rosana Wing-Shan","To, Kelvin Kai-Wang","Chan, Kwok-Hung","Cheng, Vincent Chi-Chung","Yuen, Kwok-Yung","32482633"],"abstract":["In December 2019, the coronavirus disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in the Hubei Province of China and later spread all over the world. There was an urgent need of a high-throughput molecular testing for screening the COVID-19 patients in the community. The Luminex NxTAG CoV Extended Panel is a high-throughput FDA emergency use authorized molecular diagnostic assay for SARS-CoV-2 detection. This system targets three genes (ORF1ab, N and E gene) of SARS-CoV-2, ORF1ab region of SARS-CoV and ORF5 region of MERS-CoV.In this study, we evaluated the diagnostic performance of this system with nasopharyngeal swab specimens of 214 suspected COVID-19 patients in Hong Kong. The results were compared with our routine COVID-19 RT-PCR protocol with LightMix SarbecoV E-gene kit and an in-house RdRp/Hel RT-PCR assay. The NxTAG CoV Extended panel demonstrated a 97.8% sensitivity and 100% specificity to SARS-CoV-2 in nasopharyngeal specimens. On low viral load specimens, the sensitivity of the NxTAG panel could still maintain at 85.71%. High agreement was observed between the NxTAG panel and the routine COVID-19 RT-PCR protocol (kappa value = 0.98). Overall the E gene target of the NxTAG panel demonstrated the highest sensitivity among the three SARS-CoV-2 targets while the N gene targets demonstrated the least.In conclusion, the NxTAG CoV Extended Panel is simple to use and it has high diagnostic sensitivity and specificity to SARS-CoV-2 in nasopharyngeal specimens. we recommend this diagnostic system for high-throughput COVID-19 screening in the community."],"journal":"J Clin Microbiol","authors":["Chen, Jonathan Hon-Kwan","Yip, Cyril Chik-Yan","Chan, Jasper Fuk-Woo","Poon, Rosana Wing-Shan","To, Kelvin Kai-Wang","Chan, Kwok-Hung","Cheng, Vincent Chi-Chung","Yuen, Kwok-Yung"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482633","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1128/JCM.00936-20","locations":["China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1668704334377910272,"score":390.67874},{"pmid":32396505,"title":"US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2.","text":["US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the etiologic agent associated with coronavirus disease, which emerged in late 2019. In response, we developed a diagnostic panel consisting of 3 real-time reverse transcription PCR assays targeting the nucleocapsid gene and evaluated use of these assays for detecting SARS-CoV-2 infection. All assays demonstrated a linear dynamic range of 8 orders of magnitude and an analytical limit of detection of 5 copies/reaction of quantified RNA transcripts and 1 x 10(-1.5) 50% tissue culture infectious dose/mL of cell-cultured SARS-CoV-2. All assays performed comparably with nasopharyngeal and oropharyngeal secretions, serum, and fecal specimens spiked with cultured virus. We obtained no false-positive amplifications with other human coronaviruses or common respiratory pathogens. Results from all 3 assays were highly correlated during clinical specimen testing. On February 4, 2020, the Food and Drug Administration issued an Emergency Use Authorization to enable emergency use of this panel.","Emerg Infect Dis","Lu, Xiaoyan","Wang, Lijuan","Sakthivel, Senthilkumar K","Whitaker, Brett","Murray, Janna","Kamili, Shifaq","Lynch, Brian","Malapati, Lakshmi","Burke, Stephen A","Harcourt, Jennifer","Tamin, Azaibi","Thornburg, Natalie J","Villanueva, Julie M","Lindstrom, Stephen","32396505"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the etiologic agent associated with coronavirus disease, which emerged in late 2019. In response, we developed a diagnostic panel consisting of 3 real-time reverse transcription PCR assays targeting the nucleocapsid gene and evaluated use of these assays for detecting SARS-CoV-2 infection. All assays demonstrated a linear dynamic range of 8 orders of magnitude and an analytical limit of detection of 5 copies/reaction of quantified RNA transcripts and 1 x 10(-1.5) 50% tissue culture infectious dose/mL of cell-cultured SARS-CoV-2. All assays performed comparably with nasopharyngeal and oropharyngeal secretions, serum, and fecal specimens spiked with cultured virus. We obtained no false-positive amplifications with other human coronaviruses or common respiratory pathogens. Results from all 3 assays were highly correlated during clinical specimen testing. On February 4, 2020, the Food and Drug Administration issued an Emergency Use Authorization to enable emergency use of this panel."],"journal":"Emerg Infect Dis","authors":["Lu, Xiaoyan","Wang, Lijuan","Sakthivel, Senthilkumar K","Whitaker, Brett","Murray, Janna","Kamili, Shifaq","Lynch, Brian","Malapati, Lakshmi","Burke, Stephen A","Harcourt, Jennifer","Tamin, Azaibi","Thornburg, Natalie J","Villanueva, Julie M","Lindstrom, Stephen"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396505","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3201/eid2608.201246","keywords":["2019 novel coronavirus disease","covid-19","sars-cov-2","coronavirus disease","real-time rt-pcr","real-time reverse transcription pcr","respiratory infections","severe acute respiratory syndrome coronavirus 2","viruses","zoonoses"],"locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1666627827924992000,"score":384.5624},{"pmid":32405257,"pmcid":"PMC7219399","title":"Validation of SARS-CoV-2 detection across multiple specimen types.","text":["Validation of SARS-CoV-2 detection across multiple specimen types.","Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused considerable disruption across the world, resulting in more than 235,000 deaths since December 2019. SARS-CoV-2 has a wide tropism and detection of the virus has been described in multiple specimen types, including various respiratory secretions, cerebrospinal fluid, and stool. Objective: To evaluate the accuracy and sensitivity of a laboratory modified CDCbased SARS-CoV-2 N1 and N2 assay across a range of sample types. Study Design We compared the matrix effect on the analytical sensitivity of SARS-CoV-2 detection by qRT-PCR in nasal swabs collected in viral transport medium (VTM), bronchoalveolar lavage (BAL), sputum, plasma, cerebral spinal fluid (CSF), stool, VTM, phosphate buffered saline (PBS), and Hanks' Balanced Salt Solution (HBSS). Initial limits of detection (LoD) were subsequently narrowed to confirm an LoD for each specimen type and target gene. Results: LoDs were established using a modified CDC-based laboratory developed test and ranged from a mean CT cut-off of 33.8-35.7 (10-20 copies/reaction) for the N1 gene target, and 34.0-36.2 (1-10 copies/reaction) for N2. Alternatives to VTM such as PBS and HBSS had comparable LoDs. The N2 gene target was found to be most sensitive in CSF. Conclusion: A modified CDC-based laboratory developed test is able to detect SARSCoV- 2 accurately with similar sensitivity across all sample types tested.","J Clin Virol","Perchetti, Garrett A","Nalla, Arun K","Huang, Meei-Li","Zhu, Haiying","Wei, Yulun","Stensland, Larry","Loprieno, Michelle A","Jerome, Keith R","Greninger, Alexander L","32405257"],"abstract":["Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused considerable disruption across the world, resulting in more than 235,000 deaths since December 2019. SARS-CoV-2 has a wide tropism and detection of the virus has been described in multiple specimen types, including various respiratory secretions, cerebrospinal fluid, and stool. Objective: To evaluate the accuracy and sensitivity of a laboratory modified CDCbased SARS-CoV-2 N1 and N2 assay across a range of sample types. Study Design We compared the matrix effect on the analytical sensitivity of SARS-CoV-2 detection by qRT-PCR in nasal swabs collected in viral transport medium (VTM), bronchoalveolar lavage (BAL), sputum, plasma, cerebral spinal fluid (CSF), stool, VTM, phosphate buffered saline (PBS), and Hanks' Balanced Salt Solution (HBSS). Initial limits of detection (LoD) were subsequently narrowed to confirm an LoD for each specimen type and target gene. Results: LoDs were established using a modified CDC-based laboratory developed test and ranged from a mean CT cut-off of 33.8-35.7 (10-20 copies/reaction) for the N1 gene target, and 34.0-36.2 (1-10 copies/reaction) for N2. Alternatives to VTM such as PBS and HBSS had comparable LoDs. The N2 gene target was found to be most sensitive in CSF. Conclusion: A modified CDC-based laboratory developed test is able to detect SARSCoV- 2 accurately with similar sensitivity across all sample types tested."],"journal":"J Clin Virol","authors":["Perchetti, Garrett A","Nalla, Arun K","Huang, Meei-Li","Zhu, Haiying","Wei, Yulun","Stensland, Larry","Loprieno, Michelle A","Jerome, Keith R","Greninger, Alexander L"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405257","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104438","keywords":["bal","csf","sars-cov-2","coronavirus","sensitivity","specimen type"],"topics":["Diagnosis"],"weight":1,"_version_":1666802845614080001,"score":383.68063}]}